title: Effect of fluoxetine or adenosine receptor NECA agonist on G-proteins of C6 glioma cells or NK immunocytes.
abstract: OBJECTIVE
  Neurochemical approaches to antidepressant effects and depressive disorder are also focusing on G-protein coupled receptors (GPCR) and subsequent signalling. Trimeric G-proteins play a crucial role in transmembrane signalling, its amplification and processing. It is evident that immune system participates in antidepressant mode of action by neurotransmitter GPCR.
  
  
  METHODS
  We studied the effect of acute administration of fluoxetine or NECA agonist of adenosine receptor (GPCR) on C6 glioma cells and natural killer (NK) cell line, innate immunity. We used immunochemical estimation (ELISA) of the main types of G-protein alpha subunits from isolated membranes of tested cells.
  
  
  RESULTS
  Significant reduction of G alpha q/11 subunits after acute administration of fluoxetine or NECA agonist was found. In contrast, no significant influence of G alpha s or G alpha i1,2 subunit levels of C6 glioma cells were observed. Lowered Gq/11 signalling was in accordance with decreased 2nd messenger 1,4,5 IP3 formation by PLC. Acute effect of fluoxetine or NECA agonist on NK cell line resulted in significantly reduced G alpha q/11 levels without changes in G alpha s and G alpha i1,2. Furthermore, we determined that NECA agonist was able to abolish fluoxetine-evoked G alpha q/11 levels of NK cell line.
  
  
  CONCLUSIONS
  Results show involvement of fluoxetine in the C6 glioma signal transduction and were comparable with NK cells. Similar inhibiton of G alpha q/11 by NECA agonist in both C6 glioma cells and NK cell line was determined. Furthermore NECA induced attenuation of fluoxetine evoked Galpha q/11 signalling can indicate parallel interference between GPCR and final response. Finally, we determined similarity in both interleukin 2, IL2 immunostimulator and fluoxetine evoked G q/11 levels in NK cell line and thus fluoxetine action could be related to signalling aspects of neuroimmunomodulatory activity.
authors.affiliation: 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. hkovaru@cesnet.cz
authors.forename: Hana
authors.initials: H
authors.lastname: Kovárů
authors.forename: Frantisek
authors.initials: F
authors.lastname: Kovaru
authors.forename: Petra
authors.initials: P
authors.lastname: Ondráčkova
authors.forename: Vĕra
authors.initials: V
authors.lastname: Lisá
authors.forename: Anna
authors.initials: A
authors.lastname: Fiserová
mesh_terms: D019830:Adenosine-5'-(N-ethylcarboxamide) / Q000494:pharmacology*; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D001932:Brain Neoplasms / Q000378:metabolism*; D045744:Cell Line, Tumor; D004797:Enzyme-Linked Immunosorbent Assay; D005473:Fluoxetine / Q000494:pharmacology*; D019204:GTP-Binding Proteins / Q000378:metabolism*; D005910:Glioma / Q000378:metabolism*; D006801:Humans; D007099:Imipramine / Q000494:pharmacology; D007155:Immunologic Factors / Q000494:pharmacology; D007376:Interleukin-2 / Q000378:metabolism; D007694:Killer Cells, Natural / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D011916:Rats, Inbred F344; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D019830:Adenosine-5'-(N-ethylcarboxamide); D000929:Antidepressive Agents, Tricyclic; D005473:Fluoxetine; D019204:GTP-Binding Proteins; D007099:Imipramine; D007155:Immunologic Factors; D007376:Interleukin-2; D017367:Selective Serotonin Reuptake Inhibitors